Abstract
To clarify the mechanism by which the luteinising hormone-releasing hormone agonist, buserelin, may have direct effects on breast cancer cells, factors potentially influencing its action have been studied in the MCF-7 breast cancer cell line. Oestradiol and epidermal growth factor (EGF), which stimulate the growth of MCF-7 cells in culture, reversed, at least in part, the inhibitory effects of buserelin. Insulin also abolished growth inhibition. Quantitative effects of buserelin differed according to the batch of fetal calf serum used as media supplement. These data suggest that the direct inhibitory effects of buserelin on breast cancer cells are mediated at least in part by an antagonism of growth-promoting factors.
Original language | English |
---|---|
Pages (from-to) | 1458-61 |
Number of pages | 4 |
Journal | European Journal of Cancer |
Volume | 27 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1991 |
Keywords
- Breast Neoplasms/drug therapy
- Buserelin/antagonists & inhibitors
- Cell Line
- Culture Media
- Epidermal Growth Factor/pharmacology
- Estradiol/pharmacology
- Female
- Gonadotropin-Releasing Hormone/physiology
- Humans
- Insulin/pharmacology
- Tumor Cells, Cultured/drug effects